Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Lysophosphatidic Acid Receptor 1 Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 4:42
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Pipeline Review, H2 2016’, provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711794-lysophosphatidic-acid-receptor-1-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) 
- The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/711794-lysophosphatidic-acid-receptor-1-review-h2-2016               

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Report Coverage 5 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Overview 6 
Therapeutics Development 7 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Products under Development by Stage of Development 7 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Products under Development by Therapy Area 8 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Products under Development by Indication 9 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Pipeline Products Glance 10 
Late Stage Products 10 
Early Stage Products 11 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Products under Development by Companies 12 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Therapeutics Assessment 14 
Assessment by Monotherapy/Combination Products 14 
Assessment by Mechanism of Action 15 
Assessment by Route of Administration 17 
Assessment by Molecule Type 19 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Companies Involved in Therapeutics Development 20 
Bristol-Myers Squibb Company 20 
Epigen Biosciences, Inc. 21 
F. Hoffmann-La Roche Ltd. 22 
Ono Pharmaceutical Co., Ltd. 23 
RxBio, Inc. 24 
Sanofi 25 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Drug Profiles 26 
BMS-986020 – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
BMS-986202 – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
ITMN-10534 – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
Rx-100 – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
SAR-100842 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis – Drug Profile 33
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Dormant Projects 36 
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Featured News & Press Releases 38 
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation 38 
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society 38 
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152 39 
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis 39 
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152 39 
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases 40 
Appendix 41 
Methodology 41 
Coverage 41 
Secondary Research 41 
Primary Research 41 
Expert Panel Validation 41 
Contact Us 41 
Disclaimer 42

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711794

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.